Phase 2 Readout

MPLT: Phase2_Topline: Regulation FD Disclosure.: On July 27, 2026, MapLight Therapeutics, Inc. (the "Company") will hold a conference call to discuss the topline results from ZEPHYR, a Phase 2 trial

Name: Phase2_Topline: Regulation FD Disclosure.: On July 27, 2026, MapLight Therapeutics, Inc. (the "Company") will hold a conference call to discuss the topline results from ZEPHYR, a Phase 2 trial
Start: 2026-07-27
End: 2026-07-27

July 27, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 27, 2026
Company: MapLight Therapeutics, Inc. (MPLT)

BioSniper AIPage context preserved

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Readout

Phase2_Topline: Regulation FD Disclosure.: On July 27, 2026, MapLight Therapeutics, Inc. (the "Company") will hold a conference call to discuss the topline results from ZEPHYR, a Phase 2 trial

July 27, 2026

MPLT overview →

Company: MapLight Therapeutics, Inc. (MPLT)